Expert Interview
Discussing GSK's Tebipenem HBr (Oral Carbapenem) Phase III PIVOT-PO Study in cUTIs
Ticker(s): GSKInstitution: Stanford University School of Medicine
- Associate Professor of Medicine (Infectious Diseases) and of Microbiology & Immunology at Stanford.
- Manages 60-100 patients annually with complicated urinary tract infections (including hospitalized or high-risk cases) in addition to leading translational research and intensive cohort follow-ups.
- Specializes in caring for people with immune responses to infectious disease pathogens, with a research focus on mechanisms of immunity and immunoregulation (including SARS-CoV-2 studies), and clinical trials of immune-modulatory interventions; leads and collaborates on longitudinal cohort studies and NIH-funded trials on malaria immunology, infant immune development, and immune correlates of protection.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
